Natural Alternatives International, Inc. Announces 2021 Q3 and YTD Results

Rhea-AI Summary

Natural Alternatives International (NAII) reported a net income of $1.9 million ($0.30 per diluted share) for Q3 FY2021, reversing a net loss of $4.0 million in Q3 FY2020. Net sales surged 81.8% to $46.3 million, boosted by a significant increase in private-label contract manufacturing sales, which grew 86.2%. For the nine months ending March 31, 2021, net income was $7.8 million compared to a loss of $3.4 million in the previous year. The company expects annualized FY2021 net sales to rise by 45% to 55%, while also maintaining strong cash reserves of $28.1 million.

Positive

• Net income increased to $1.9 million for Q3 FY2021, compared to a loss of $4.0 million in Q3 FY2020.
• Net sales rose 81.8% to $46.3 million for Q3 FY2021.
• Private-label contract manufacturing sales increased 86.2% during the same period.
• For the nine months ending March 31, 2021, net income reached $7.8 million, up from a loss of $3.4 million.
• Annualized net sales for FY2021 are expected to increase by 45% to 55%.
• Strong cash reserves of $28.1 million and working capital of $53.8 million as of March 31, 2021.

Negative

• CarnoSyn® beta-alanine royalty and licensing revenue decreased 7.1% to $9.6 million for the first nine months of FY2021 compared to FY2020.

CARLSBAD, Calif., May 13, 2021 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $1.9 million, or $0.30 per diluted share, on net sales of $46.3 million for the third quarter of fiscal year 2021 compared to a net loss of $4.0 million, or $0.61 per diluted share, in the third quarter of the prior fiscal year.  Our results for the third quarter of fiscal 2020 included the negative impact of a $4.3 million accounts receivable and inventory reserve related to a former customer, which was not repeated in the third quarter of fiscal 2021. 

Net sales during the three months ended March 31, 2021 increased $20.8 million, or 81.8%, from $25.5 million recorded in the comparable prior year period.  During the same period, private-label contract manufacturing sales increased $19.5 million, or 86.2%, from the comparable quarter last year. Private-label contract manufacturing sales increased for a majority of our distribution channels worldwide primarily due to increased shipments of existing products and sales of newly awarded products to new and existing customers.  CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 45.6% to $4.1 million during the third quarter of fiscal 2021, as compared to $2.8 million for the third quarter of fiscal 2020.  CarnoSyn® sales increased primarily due to an increase in material shipments resulting from higher sales to existing customers and the increase in athletic activities as gyms and athletic facilities began to reopen in accordance with easing COVID-19 guidelines for various cities and states across the USA.

Net income for the nine months ended March 31, 2021 was $7.8 million, or $1.22 per diluted share, compared to a net loss of $3.4 million, or $0.51 per diluted share, for the nine months ended March 31, 2020.

Net sales during the nine months ended March 31, 2021 increased $50.3 million, or 60.1%, from $83.8 million recorded in the comparable prior year period.  For the nine months ended March 31, 2021, private-label contract manufacturing sales increased $51.1 million, or 69.5%, from the comparable period last year. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 7.1% to $9.6 million during the first nine months of fiscal 2021, as compared to $10.3 million for first nine months of fiscal 2020. 

Based on our current sales order volumes and future period sales forecasts received from our customers, we now expect our annualized fiscal 2021 net sales to increase between 45% and 55% compared to fiscal 2020.  We also expect to generate operating income between 7% and 9% of net sales for our fiscal year ending June 30, 2021.

As of March 31, 2021, we had cash of $28.1 million and working capital of $53.8 million compared to $30.5 million and $51.2 million, respectively, as of June 30, 2020.  As of March 31, 2021, we had $10.0 million available under our line of credit agreement.

Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, "Sales and profitability for the first nine months of this fiscal year represent a new record for our company.  Additionally, we continue to maintain a significant pipeline of orders for delivery in the coming months, and as a result have modified our outlook for the remainder of the year. While maintaining an enviable balance sheet, we are also seizing opportunities as presented to secure inventories for our future needs.  This has been challenging for a variety of logistical concerns as issues with COVID-19 management have impacted supply-chains around the world.  Nevertheless, we are planning for a robust future as it is clear to us that consumer trends involving making healthier choices will continue to be an enduring dividend from the difficulties of the past year."

"The dietary supplement industry continues to report robust demand for product and we are in line with that industry trend.  We think this supports our belief this trend will continue and is not just a temporary effect of the COVID-19 pandemic."

"We continue to seek additional growth opportunities both organic and strategic and we believe we are well positioned to take advantage of such opportunities based on our strong working capital position, available capacity, and stellar reputation for excellence within our industry.  NAI is the first and currently only company in our industry to be audited and certified by the Supplement Safety Compliance Initiative (SSCI), a retailer led initiative to bolster supply chain and consumer confidence for their member's nutritional supplement products.  The implications for this certification are immense given that major retailers, both in brick and mortar as well as online are increasingly requiring this type of certification to permit products to be sold through their channels." 

An updated investor presentation will be posted to the investor relations page on our website later today (https://www.nai-online.com/our-company/investors/). 

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers.  Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://www.nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information.  These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, the impact of COVID-19, our future revenue profits and financial condition, our ability to  maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein.  NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or investor@nai-online.com.

Web site: http://www.nai-online.com

 

NATURAL ALTERNATIVES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
(Unaudited)
	Three Months Ended								Nine Months Ended
	March 31,								March 31,
	2021				2020				2021				2020
NET SALES	$46,320		100.0%		$25,482		100.0%		$134,129		100.0%		$83,780		100.0%
Cost of goods sold	39,484		85.2%		22,588		88.6%		111,614		83.2%		71,441		85.3%
Gross profit	6,836		14.8%		2,894		11.4%		22,515		16.8%		12,339		14.7%
Selling, general & administrative expenses	4,136		8.9%		7,117		27.9%		12,338		9.2%		15,919		19.0%
INCOME (LOSS) FROM OPERATIONS	2,700		5.8%		(4,223)		-16.6%		10,177		7.6%		(3,580)		-4.3%
Other (loss) income, net	(326)		-0.7%		(48)		-0.2%		(1,453)		-1.1%		5		0.0%
INCOME (LOSS) BEFORE TAXES	2,374		5.1%		(4,271)		-16.8%		8,724		6.5%		(3,575)		-4.3%
Income tax expense (benefit)	458				(256)				918				(132)
NET INCOME (LOSS)	$  1,916				$ (4,015)				$    7,806				$ (3,443)
NET INCOME (LOSS) PER COMMON SHARE:
Basic:	$0.31				($0.61)				$1.24				($0.51)
Diluted:	$0.30				($0.61)				$1.22				($0.51)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	6,201				6,565				6,296				6,734
Diluted	6,327				6,565				6,401				6,734

 

NATURAL ALTERNATIVES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
	(Unaudited)
	March 31,		June 30,
	2021		2020
ASSETS
Cash and cash equivalents	$28,089		$30,478
Accounts receivable, net	16,882		17,001
Inventories, net	29,088		27,972
Other current assets	3,166		3,573
Total current assets	77,225		79,024
Property and equipment, net	22,456		21,523
Operating lease right-of-use assets	16,551		18,354
Other noncurrent assets, net	2,229		1,302
Total Assets	$118,461		$120,203
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	25,411		20,046
Line of credit	-		10,000
Long-term liability - operating leases	17,026		18,782
Total Liabilities	42,437		48,828
Stockholders' Equity	76,024		71,375
Total Liabilities and Stockholders' Equity	$118,461		$120,203

 

View original content:http://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-2021-q3-and-ytd-results-301291244.html

SOURCE Natural Alternatives International, Inc.

FAQ

What were Natural Alternatives International's earnings for Q3 FY2021?

Natural Alternatives International reported a net income of $1.9 million, or $0.30 per diluted share, for Q3 FY2021.

How did net sales perform for Natural Alternatives International in Q3 FY2021?

Net sales for Q3 FY2021 increased by 81.8% to $46.3 million compared to Q3 FY2020.

What is the expected growth rate for Natural Alternatives International's annualized net sales for FY2021?

The company expects its annualized net sales for FY2021 to increase by 45% to 55% compared to FY2020.

What was the net income for the nine months ending March 31, 2021, for NAII?

For the nine months ending March 31, 2021, Natural Alternatives International reported a net income of $7.8 million.

What challenges are affecting Natural Alternatives International's supply chain?

The company noted logistical challenges due to COVID-19 management impacting global supply chains.